🔎 Trials Near Me

Utama › Leukemia Biphenotipik Akut › Maryland

Kajian klinikal Leukemia Biphenotipik Akut di Maryland

4 kajian untuk Leukemia Biphenotipik Akut sedang mencari peserta di lokasi di Maryland.

Bandar di Maryland

Teks kajian rasmi (Bahasa Inggeris)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Mengambil pesertaFasa 2
365 Days · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • dan 1 lagi
Mengambil pesertaFasa 3
365 Days – 25 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Mengambil pesertaFasa 1/2
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Johns Hopkins University, Baltimore
  • National Cancer Institute, Pediatric Oncology Branch, Bethesda
Mengambil pesertaFasa 1
Umur 1 hingga 21 · Semua jantina · Dikemas kini 6 Dis 2024 · NCT05476770

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.